VERTEX PHARMACEUTICALS INC (VRTX)       323.1  +3.12 (+0.98%)

Company Profile

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 3,900 full-time employees. The firm is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The firm's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The firm has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.

Company Info

VERTEX PHARMACEUTICALS INC

50 Northern Avenue

Boston MASSACHUSETTS 02210

P: 16173416393.0

CEO: Reshma Kewalramani

Employees: 3900

Website: https://www.vrtx.com/